NanoViricides, Inc. (NNVC) Files Year End Report and Discusses Financial Strength
Today, NanoViricides, Inc. reported that it filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC). Nano Viricides estimates that its year-end cash in hand should be sufficient for an additional eighteen months or more of operational expenses. The company also believes that its finances are sufficient enough to advance its drug pipeline further into the FDA approval process. NanoVircides had cash, cash equivalents and prepaid expenses balances totaling approximately $9.556 million at the end of June 2011. As of one year ago, the company reported a total balance of $7.456 million. This year,…